$2.69 $0.11 (4.3%)

04:30 PM EDT on 08/04/20

Neovasc Inc (NASDAQ:NVCN)

CAPS Rating: No stars

Current Price $2.69 Mkt Cap $44.9M
Open $2.56 P/E Ratio 0.00
Prev. Close $2.58 Div. (Yield) $0.00 (0.0%)
Daily Range $2.56 - $2.70 Volume 174,968
52-Wk Range $1.24 - $8.65 Avg. Daily Vol. 400,015


How do you think NASDAQ:NVCN will perform against the market?

Add Stock to CAPS Watchlist

All Players

5 Outperform
0 Underperform

All-Star Players

0 Outperform
0 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:NVCN Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Bigsef77 (70.02)
Submitted January 29, 2019

Neovasc Receives Approval to Proceed with Phase 2 of TIARA-II Study from Clinical Regulators in Germany and the UK[CNW Group]CNW Group•January 29, 2019Successfully completed all Phase 1 requirements of TIARA-IINASDAQ, TSX: NVCNVANCOUVER , Jan 29,… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!



Recent Community Commentary

Read the most recent pitches from players about NVCN.


Member Avatar Bigsef77 (70.02) Submitted: 1/29/2019 10:56:38 AM : Outperform Start Price: $31.10 NASDAQ:NVCN Score: -104.07

Neovasc Receives Approval to Proceed with Phase 2 of TIARA-II Study from Clinical Regulators in Germany and the UK
[CNW Group]
CNW Group•January 29, 2019

Successfully completed all Phase 1 requirements of TIARA-II


VANCOUVER , Jan 29, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that it has completed the Phase 1 requirements of the TIARA-II study required by the bi-phasic study design in both Germany and the United Kingdom and has received approval to proceed with Phase 2 of the TIARA-II study for its Tiara™ transcatheter mitral valve replacement device (the "Tiara"). This approval comes following Clinical Events Committee adjudication of adverse events, Data and Safety Monitoring Board review of the data, and Governmental regulatory and ethics committees reviews of the interim clinical report provided for 20 implanted subjects. This approval will allow the TIARA-II study to proceed in these geographies with no restrictions.

The TIARA-II study is an international, multicenter, single-arm, prospective, non-randomized, safety and performance clinical study. The total enrollment goal for the study in all geographies is 115 implanted subjects.

"The Neovasc team is excited about the positive news from the governmental healthcare authorities in Germany and the UK, as well as from the independent ethics committees in both countries. After their review of the submitted, detailed results of the first 20 Tiara implants, we received all required approvals to continue this TIARA-II clinical study into the second and final phase of full enrollment, without further restrictions," commented Fred Colen , Neovasc's President and Chief Executive Officer.


Find the members with the highest scoring picks in NVCN.

Score Leader


ClientNein (99.97) Score: +188.77

The Score Leader is the player with the highest score across all their picks in NVCN.

Member Name Member
Call Time
Score Commentary
gunterle 68.73 5/29/2020 Outperform 5Y $2.91 -7.22% +9.30% -16.52 0 Comment
ravipg2w < 20 4/14/2020 Outperform 3W $3.15 -14.29% +16.78% -31.07 0 Comment
Maddentycoon 24.23 2/15/2019 Outperform 3W $6.84 -60.53% +19.43% -79.96 0 Comment
Bigsef77 70.02 10/3/2018 Outperform 3Y $31.10 -91.32% +12.75% -104.07 1 Comment
tstapez22 29.81 10/23/2018 Outperform 5Y $22.80 -88.16% +21.82% -109.97 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for NVCN.